Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.65 |
| ▸ | NPY4R | P50391 | 10/20 | 0.57 |
| ▸ | NPY1R | P25929 | 8/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.57 |
| ▸ | NPY2R | P49146 | 4/20 | 0.56 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.54 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31315032 | 0.91 | NPY4R (0.60) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31757517 | 0.89 | NPY4R (0.54) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29430569 | 0.88 | TFPI (0.70) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30601869 | 0.87 | TFPI (0.79) | TFPIVIPR2VIPR1 | |
| SCHEMBL29461387 | 0.87 | TFPI (0.63) | TFPIVIPR2VIPR1 | |
| SCHEMBL29794100 | 0.87 | TFPI (0.67) | TFPINPY4RNPY1RNPY5RVIPR2 | |
| SCHEMBL10535233 | 0.86 | TFPI (0.62) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL10535214 | 0.86 | TFPI (0.62) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30536310 | 0.86 | TFPI (0.61) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30512673 | 0.86 | TFPI (0.64) | TFPINPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113730551-B | Application of MMI-0100 short peptide compound in preparation of medicine for treating cholestatic liver disease | 徐州医科大学 | 2022-11-25 | — | — | CN | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12497401-B2 | Substituted tetrazoles as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-12-16 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250250252-A1 | PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-07 | — | — | US | disclosed |
| US-20250250251-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2025-08-07 | — | — | US | disclosed |
| EP-4171563-B1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-08-06 | — | — | EP | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | disclosed |
| CN-114616224-A | Novel tricyclic 5-HT2Antagonists | 安娜玛有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114555601-A | Novel tetrazoles | 勃林格殷格翰国际有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3986865-A1 | NEW TRICYCLIC 5-HT2 ANTAGONISTS | AnaMar AB (SE) | 2022-04-27 | — | — | EP | disclosed |
| US-20220112210-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2022-04-14 | — | — | US | disclosed |
| US-20220112202-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114144229-A | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | 梅约医学教育与研究基金会 | 2022-03-04 | — | — | CN | disclosed |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | disclosed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250252-A1 | PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | TFPI 2279/4885NPY4R 1391/4885NPY1R 1466/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | TFPI 986/4885NPY4R 15/4885NPY1R 13/4885 |
| US-20220112202-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | TFPI 322/4885NPY4R 1966/4885NPY1R 1033/4885 |
| US-20220112210-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | TFPI 322/4885NPY4R 1966/4885NPY1R 1033/4885 |
| US-20250250251-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | QPCT, QPCTL, GLUL | TFPI 2299/4885NPY4R 1844/4885NPY1R 1803/4885 |
| US-12497401-B2 | Substituted tetrazoles as TRPA1 inhibitors | TRPA1, TRPV1, TRPV2 | TFPI 67/4885NPY4R 1992/4885NPY1R 1474/4885 |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | TFPI 322/4885NPY4R 2014/4885NPY1R 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.